Wednesday, February 10, 2010, 12:25PM AEST - The Australian Stockmarket closes in 3 hours and 40 minutes.
To create a watchlist or portfolio of shares, Register

Idera Pharmaceuticals, Inc. (IDRA)

 8:00AM AEST: 4.70 USD  Up 0.04 (0.86%)  
 MORE ON IDRA 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Idera Pharmaceuticals, Inc. (NGM:IDRA) Delayed quote dataEdit
Last Trade:4.70 USD
Trade Time: 8:00AM AEST
Change:Up 0.04 (0.86%)
Prev Close:4.66
Open:4.64
Bid:3.90 x 100
Ask:5.46 x 100
1y Target Est:16.00
Day's Range:4.64 - 4.77
52wk Range:4.48 - 8.50
Volume:20,332
Avg Vol (3m):49,507.9
Market Cap:110.31M
P/E (ttm):28.66
EPS (ttm):0.16
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add IDRA to Portfolio   Download Data

 HEADLINES 
•Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indications
Business Wire (Thu, Jan 28)
•IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Thu, Jan 28)
•Idera Pharma names MacCoss to board of directors
AP (Wed, Jan 27)
•Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss, Ph.D., to Its Board of Directors
Business Wire (Wed, Jan 27)
•[$$] Small-Caps Get a Lift From Health Sector
at The Wall Street Journal Online (Wed, Jan 20)
•Idera Pharmaceuticals Announces Achievement of Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
Business Wire (Tue, Jan 19)
•Idera Pharmaceuticals Announces Positive Interim Data from Phase 1 Clinical Trial of IMO-2125 in Chronic Hepatitis C Patients
Business Wire (Tue, Dec 22)
•IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Sat, Dec 19)
•Idera Pharmaceuticals Appoints Rahul Jasuja, Ph.D., Vice President of Corporate Development
Business Wire (Sat, Dec 5)
•Idera: Novartis deal ends, Merck pact extended
AP (Thu, Nov 26)
More Headlines for IDRA...
 ANALYST 
EPS Est (next year) (Dec-09) :0.15
EPS Est (in 2 years) (Dec-10) :0.01
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccin...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices